Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia.
A549 Cells
Apoptosis
Carcinoma, Non-Small-Cell Lung
/ metabolism
Cell Hypoxia
Histone Deacetylase Inhibitors
/ pharmacology
Histone Deacetylases
/ metabolism
Humans
Lung Neoplasms
/ metabolism
Lysine
/ chemistry
Machine Learning
Metabolic Networks and Pathways
Oxidative Phosphorylation
Oxygen
/ chemistry
Proteome
/ metabolism
Proteomics
/ methods
Proto-Oncogene Proteins p21(ras)
/ metabolism
Reactive Oxygen Species
/ metabolism
NSCLC
cancer metabolism
hypoxia
lysine deacetylase inhibitors
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Mar 2021
25 Mar 2021
Historique:
received:
25
02
2021
revised:
19
03
2021
accepted:
22
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
12
6
2021
Statut:
epublish
Résumé
Growing evidence is showing that acetylation plays an essential role in cancer, but studies on the impact of KDAC inhibition (KDACi) on the metabolic profile are still in their infancy. Here, we analyzed, by using an iTRAQ-based quantitative proteomics approach, the changes in the proteome of
Identifiants
pubmed: 33806075
pii: ijms22073378
doi: 10.3390/ijms22073378
pmc: PMC8036653
pii:
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
KRAS protein, human
0
Proteome
0
Reactive Oxygen Species
0
Histone Deacetylases
EC 3.5.1.98
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Lysine
K3Z4F929H6
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agència de Gestió d'Ajuts Universitaris i de Recerca
ID : 2017SGR1033
Organisme : Ministerio de Economía y Empresa
ID : SAF2017-89673-R
Organisme : Ministerio de Educación y Formación Profesional
ID : FPU14-05992
Références
Cancers (Basel). 2020 Jun 23;12(6):
pubmed: 32585896
Nat Mater. 2019 May;18(5):435-441
pubmed: 31000803
Oncogene. 2010 May 20;29(20):2962-72
pubmed: 20228846
J Cell Biochem. 2009 Jul 1;107(4):600-8
pubmed: 19459166
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
Crit Rev Oncol Hematol. 2018 May;125:41-47
pubmed: 29650275
Clin Cancer Res. 2015 Mar 15;21(6):1360-72
pubmed: 25547679
Front Genet. 2020 Sep 11;11:578011
pubmed: 33024443
J Surg Res. 2007 Oct;142(2):219-26
pubmed: 17612559
PLoS One. 2016 Dec 30;11(12):e0168519
pubmed: 28036387
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Cell Mol Med. 2019 Apr;23(4):2872-2889
pubmed: 30710424
FEBS J. 2018 Jan;285(1):28-41
pubmed: 28570035
Cancers (Basel). 2020 Jun 18;12(6):
pubmed: 32570729
Mol Aspects Med. 2010 Apr;31(2):145-70
pubmed: 20206201
Trends Biochem Sci. 2011 Feb;36(2):108-16
pubmed: 20934340
Br J Cancer. 2012 Jan 3;106(1):116-25
pubmed: 22158273
Int J Oncol. 2013 Jan;42(1):359-66
pubmed: 23165748
Biochem J. 2012 May 1;443(3):735-46
pubmed: 22339555
Trends Cancer. 2017 Mar;3(3):169-180
pubmed: 28393116
Mol Cell Oncol. 2014 Oct 29;1(3):e963452
pubmed: 27308346
Anticancer Res. 2018 Jan;38(1):37-43
pubmed: 29277754
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Nucleic Acids Res. 2021 Jan 8;49(D1):D1144-D1151
pubmed: 33237278
Nucleic Acids Res. 2021 Jan 8;49(D1):D1138-D1143
pubmed: 33068428
Am J Respir Crit Care Med. 2005 Jun 1;171(11):1279-85
pubmed: 15735062
J Cell Biol. 2012 Jul 23;198(2):155-64
pubmed: 22826120
J Clin Oncol. 2012 Jun 20;30(18):2280-2
pubmed: 22508823
Front Cell Dev Biol. 2020 Jun 03;8:425
pubmed: 32582706
Int J Oncol. 2005 Aug;27(2):473-9
pubmed: 16010430
Mol Cell Biol. 2006 Mar;26(6):2019-28
pubmed: 16507982
Curr Cancer Drug Targets. 2020;20(6):392-409
pubmed: 32101123
J Biomed Sci. 2017 Jun 14;24(1):37
pubmed: 28615068
J Proteomics. 2019 Mar 20;195:114-124
pubmed: 30660770
Ann Thorac Surg. 2006 Mar;81(3):1034-42
pubmed: 16488717
Nucleic Acids Res. 2014 Jan;42(Database issue):D358-63
pubmed: 24234451
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Curr Protoc Bioinformatics. 2020 Mar;69(1):e93
pubmed: 31945268
Nanotoxicology. 2019 Oct;13(8):1021-1040
pubmed: 31132913
Front Oncol. 2019 Aug 30;9:848
pubmed: 31544066
Oncogene. 2011 Jun 30;30(26):2986-96
pubmed: 21358671
Sci Rep. 2015 Mar 31;5:9520
pubmed: 25825284
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancer Sci. 2007 Sep;98(9):1394-401
pubmed: 17608771
Nature. 2009 Apr 23;458(7241):1056-60
pubmed: 19262508
Mol Cancer. 2007 Sep 26;6:61
pubmed: 17894897
J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S404-6
pubmed: 23160335
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Clin Cancer Res. 2008 Jul 15;14(14):4417-26
pubmed: 18579664
Biofactors. 2009 Mar-Apr;35(2):209-25
pubmed: 19449450
Mol Cancer Ther. 2008 Jul;7(7):1923-30
pubmed: 18606719
Cancer Res. 2011 Jan 1;71(1):13-8
pubmed: 21199794
Mol Cancer Ther. 2008 Oct;7(10):3285-97
pubmed: 18852132
Mol Cancer Ther. 2003 Dec;2(12):1273-84
pubmed: 14707268
J Cheminform. 2013 Jun 22;5(1):30
pubmed: 23800010
Sci Rep. 2015 Jul 23;5:12291
pubmed: 26201611
Eur J Haematol. 2009 Jun;82(6):440-9
pubmed: 19220424
Int J Oncol. 2010 Oct;37(4):869-77
pubmed: 20811709
Int J Cancer. 2007 Jan 1;120(1):24-31
pubmed: 17019711
Cell. 2008 May 16;133(4):612-26
pubmed: 18485870
Radiother Oncol. 2016 Mar;118(3):453-9
pubmed: 26861738
Cancer Cell. 2016 Sep 12;30(3):418-431
pubmed: 27622334
PLoS One. 2011;6(7):e22264
pubmed: 21789245
Cancer Chemother Pharmacol. 2006 Dec;58(6):776-84
pubmed: 16532342
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8788-93
pubmed: 20421486
Cell Death Dis. 2016 Jan 21;7:e2063
pubmed: 26794658
Front Oncol. 2021 Feb 23;11:559822
pubmed: 33708620
Gene. 2016 Jun 10;584(1):75-82
pubmed: 26976343
Proc Nutr Soc. 2011 Feb;70(1):92-9
pubmed: 21067629
Nat Methods. 2013 Aug;10(8):690-1
pubmed: 23900247
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Cell Metab. 2011 Aug 3;14(2):151-3
pubmed: 21803285
Mol Cancer. 2019 Nov 11;18(1):157
pubmed: 31711497
Protein Cell. 2014;5(8):592-602
pubmed: 25015087
Sci Rep. 2016 Mar 09;6:22831
pubmed: 26956544
Nucleic Acids Res. 2020 Jan 8;48(D1):D504-D510
pubmed: 31665520
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
FEBS Lett. 2004 Jul 2;569(1-3):1-6
pubmed: 15225599
Mol Cell Proteomics. 2015 Nov;14(11):2936-46
pubmed: 26209610
Nat Protoc. 2010 Sep;5(9):1574-82
pubmed: 21085123
PLoS One. 2012;7(11):e47519
pubmed: 23139748
Open Life Sci. 2019 Dec 31;14:619-627
pubmed: 33817200
J Proteome Res. 2011 Jun 3;10(6):2758-66
pubmed: 21526793
Cell Physiol Biochem. 2013;31(1):92-101
pubmed: 23363613
Nucleic Acids Res. 2019 Jan 8;47(D1):D529-D541
pubmed: 30476227
Chin Med J (Engl). 2013 Jan;126(1):129-34
pubmed: 23286491
Nucleic Acids Res. 2019 Jan 8;47(D1):D550-D558
pubmed: 30357405
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Science. 2010 Feb 19;327(5968):1000-4
pubmed: 20167786
Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954
pubmed: 27899562
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Autophagy. 2015;11(2):225-38
pubmed: 25607466
Mol Cell Proteomics. 2017 Nov;16(11):1906-1921
pubmed: 28874504
Expert Rev Anticancer Ther. 2017 Aug;17(8):693-702
pubmed: 28657372
Cancer Sci. 2012 Nov;103(11):1946-54
pubmed: 22863020
J Immunol Methods. 1995 Jul 17;184(1):39-51
pubmed: 7622868
KDD. 2016 Aug;2016:855-864
pubmed: 27853626
Mol Pharm. 2016 Jul 5;13(7):2524-30
pubmed: 27200455
Cell Rep. 2016 Aug 9;16(6):1614-1628
pubmed: 27477280
Br J Cancer. 2013 May 28;108(10):2021-32
pubmed: 23632475
Biochem Pharmacol. 2014 Mar 1;88(1):119-27
pubmed: 24447935
J Exp Med. 2005 Mar 21;201(6):925-35
pubmed: 15781583
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Cancer Res. 2016 Jun 1;76(11):3295-306
pubmed: 27020861
Clin Cancer Res. 2018 Feb 15;24(4):972-984
pubmed: 29246941
PLoS One. 2011;6(7):e21924
pubmed: 21789194
Oncogene. 2020 Apr;39(14):2948-2960
pubmed: 32034305
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
Oncol Lett. 2012 Dec;4(6):1151-1157
pubmed: 23226794
FEBS J. 2013 Feb;280(3):775-93
pubmed: 23181831
Target Oncol. 2009 Jan;4(1):45-56
pubmed: 19343301
J Hematol Oncol. 2019 Dec 9;12(1):134
pubmed: 31815659
Cancer Biol Med. 2019 Aug;16(3):435-461
pubmed: 31565476
Cell Metab. 2012 May 2;15(5):675-90
pubmed: 22560220
Cell Death Differ. 2014 Aug;21(8):1185-97
pubmed: 24632950
Cancer Cell. 2008 Jun;13(6):472-82
pubmed: 18538731
Sci China Life Sci. 2017 Jan;60(1):94-97
pubmed: 27888384
Biomed Pharmacother. 2010 Feb;64(2):88-92
pubmed: 20005069
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Proteome Res. 2014 May 2;13(5):2297-313
pubmed: 24702160
Clin Cancer Res. 2014 May 15;20(10):2714-26
pubmed: 24644001
Oncotarget. 2017 Apr 27;8(34):57733-57754
pubmed: 28915708
Genome Med. 2016 May 12;8(1):55
pubmed: 27175787
Mol Syst Biol. 2017 Oct 4;13(10):940
pubmed: 28978620
Mol Cell. 2010 Jun 25;38(6):864-78
pubmed: 20620956
Sci Rep. 2020 Jan 20;10(1):727
pubmed: 31959767
Int J Proteomics. 2015;2015:678527
pubmed: 26421188
Int J Cancer. 2014 Jun 1;134(11):2560-71
pubmed: 24374738
Chembiochem. 2020 Jun 2;21(11):1647-1655
pubmed: 31919953
Mol Cancer Ther. 2017 Dec;16(12):2656-2667
pubmed: 28878027
J Cheminform. 2015 Jul 14;7:34
pubmed: 26175801
Cell. 2010 Jan 22;140(2):280-93
pubmed: 20141841
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Cell Rep. 2016 Oct 11;17(3):821-836
pubmed: 27732857
J Proteome Res. 2014 Nov 7;13(11):4695-704
pubmed: 25029028
Clin Cancer Res. 2014 Sep 15;20(18):4737-9
pubmed: 24916696